Effect of atorvastatin on hs-CRP in acute coronary syndrome
| Autor: | Sandeep Chopra, Dinesh K Badyal, Thannikot M. Jaison, Prem P. Khosla, Ankur Gupta, Bharti Uppal |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male medicine.medical_specialty Acute coronary syndrome Atorvastatin Short Report Coronary Disease Group B Internal medicine Humans Medicine Pyrroles Pharmacology (medical) Prospective Studies cardiovascular diseases Acute Coronary Syndrome Prospective cohort study Pharmacology Dose-Response Relationship Drug biology business.industry Anticholesteremic Agents C-reactive protein Acute-phase protein nutritional and metabolic diseases Cholesterol LDL Middle Aged medicine.disease Lipids Hydroxymethylglutaryl-CoA reductase C-Reactive Protein Treatment Outcome Endocrinology Heptanoic Acids HMG-CoA reductase biology.protein Cardiology Female lipids (amino acids peptides and proteins) business medicine.drug |
| Zdroj: | British Journal of Clinical Pharmacology. 66:411-413 |
| ISSN: | 1365-2125 0306-5251 |
| DOI: | 10.1111/j.1365-2125.2008.03172.x |
| Popis: | WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Markers of inflammation are being investigated as predictors of coronary ischaemic events. All major statins have shown almost similar and significant efficacy in reducing C-reactive protein (CRP) concentrations in acute coronary syndrome (ACS), but atorvastatin was used in a high dose (80 mg). • This study was designed to evaluate the effect of a lower dose (20 mg) of atorvastatin on hs-CRP concentrations in patients with ACS. WHAT THIS STUDY ADDS • A lower dose of atorvastatin (20 mg) was effective in decreasing hs-CRP and LDL concentrations in as short a duration as 4 weeks. The use of a lower dose of atorvastatin in patients of ACS can offer an attractive approach for early treatment of ACS patients. AIMS To evaluate the effect of a lower dose (20 mg) of atorvastatin on hs-CRP concentrations in patients with ACS. METHODS Group A (n = 50) patients received atorvastatin 20 mg day−1 for 4 weeks in addition to standard anti-anginal treatment. Group B (n = 50) patients received standard anti-anginal treatment without atorvastatin. RESULTS hs-CRP concentrations decreased in both groups, but the decrease was greater in group A. The decrease in hs-CRP was also significantly greater in the subgroups of smoking, hypertension and past history of cardiovascular disease with atorvastatin. CONCLUSIONS The use of a lower dose (20 mg) of atorvastatin can offer an attractive approach for early treatment of patients with ACS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text